Riders on the Storm Part 1: What the FY2027 Appropriations Report Means for FDA By Jennifer D. Newberger & Sara W. Koblitz & Deborah L. Livornese & Dara Katcher Levy & Mark A. Tobolowsky & Kalie E. Richardson & Riëtte van Laack & Mary Bass —

https://www.thefdalawblog.com/2026/06/riders-on-the-storm-part-1-what-the-fy2027-appropriations-report-means-for-fda/?utm_source=rss&utm_medium=rss&utm_campaign=riders-on-the-storm-part-1-what-the-fy2027-appropriations-report-means-for-fda On May 1, 2026, the House Committee on Appropriations submitted House Report 119-632 to accompany H.R. 8646—the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2027, which passed on June 4, 2026. The report serves as the Committee’s explanation of the accompanying bill, setting forth funding levels, programmatic directives, and policy priorities across the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), the Commodity Futures Trading Commission (CFTC), and the Farm Credit Administration (FCA). Given that of these acronyms our blog has only FDA in the title, it should come as no surprise that we are focused only on the FDA provisions, of which there are plenty—so many that we needed to split the post into three parts. The first, published today, will cover a few key provisions from the Act and the cross-product riders. Post 2 will look at the drug-specific provisions (including biosimilars). And Post 3 will look at everything else, including devices and compounding.